Linifanib is a potent inhibitor of receptor tyrosine kinases, particularly targeting vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR). It has been investigated primarily in oncology for its anti-angiogenic properties, meaning it helps block the formation of new blood vessels that tumors need to grow and spread. Due to this mechanism, linifanib has been studied in clinical trials for various cancers, including hepatocellular carcinoma and non-small cell lung cancer. It shows potential in slowing tumor progression and improving patient outcomes when used as a targeted therapy, especially in cases where other treatments have failed. Research continues to explore its efficacy and safety in combination with other anticancer agents.